𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The ELSA: The development and clinical use of a new endoscopic tissue remover

✍ Scribed by M. J. Coptcoat; K. T. Ison; A. Timoney; J. E. A. Wickham

Book ID
105261657
Publisher
Springer-Verlag
Year
1989
Tongue
English
Weight
681 KB
Volume
7
Category
Article
ISSN
0724-4983

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Development and clinical use of the new
Development and clinical use of the new gastrointestinal prokinetic drug cisapride (R 51 619)
✍ AndrΓ© Reyntjens; Marleen Verlinden; Tonny Aerts πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 730 KB

Cisapride is a new gastrointestinal prokinetic substance that is devoid of antidopaminergic and direct muscarinic activity. This was evidenced by a lack of effect on prolactin release and gastric secretion. In man, cisapride stimulates lower esophageal, gastric, small intestinal, and colonic motilit

Clinical validation of the new ELSA-CA 1
Clinical validation of the new ELSA-CA 125 II assay: Report of a european multicentre evaluation
✍ Maryvonne Clement; Paul Bischof; Claire Gruffat; Gabriel Ricolleau; Eliane Auvra πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 French βš– 472 KB

The ELSA-CA 125 II is a second-generation radioimmunoassay for the quantification of CA I25 in serum. In a multicentre study involving 49 follow-ups of patients with ovarian cancers, and 880 other patients, 2.8% of healthy persons, 25% of 149 patients with benign gynaecological diseases and 39% of 8